The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins TM , a new class of programmable medicines that aims to redefine what therapeutics can achieve for patients The company emerges after 3 years of platform development and an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass. , July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins TM . Synteins are computationally-generated and synthesized with novel building blocks, endowing them with extraordinary properties to bring life-changing treatments to patients across a wide range of diseases.
Flagship has initially committed $50 million to advance the company's platform and develop a diverse pipeline of medicines, with an initial focus on oncology and immunology indications. "Biologics have transformed medicine in the past forty years, but only a fraction of their potential has been realized because we've been limited by the boundaries of nature," said Noubar Afeyan , Ph.D.
, Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Abiologics. "With the convergence of advancements in generative artificial intelligence, automated polymer synthesis and chemical functionalization coupled with a vision to develo.